Stockreport

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

Tarsus Pharmaceuticals, Inc.  (TARS) 
PDF Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlight [Read more]